

ELECTRONIC LETTER

Exonic *STK11* deletions are not a rare cause of Peutz-Jeghers syndrome

N C M Hearle, M F Rudd, W Lim, V Murday, A G Lim, R K Phillips, P W Lee, J O'Donohue, P J Morrison, A Norman, S V Hodgson, A Lucassen, R S Houlston

J Med Genet 2006;43:e15 (<http://www.jmedgenet.com/cgi/content/full/43/4/e15>). doi: 10.1136/jmg.2005.036830

Background: Peutz-Jeghers syndrome (PJS) is a rare, autosomal dominant cancer predisposition syndrome characterised by oro-facial pigmentation and hamartomatous polyposis of the gastrointestinal tract. A causal germline mutation in *STK11* can be identified in 30% to 80% of PJS patients.

Methods: Here we report the comprehensive mutational analysis of *STK11* in 38 PJS probands applying conventional PCR based mutation detection methods and the recently introduced MLPA (multiplex ligation dependent probe amplification) technique developed for the identification of exonic deletions/duplications.

Results: Nineteen of 38 probands (50%) had detectable point mutations or small scale deletions/insertions and six probands (16%) had genomic deletions encompassing one or more *STK11* exons.

Conclusions: These findings demonstrate that exonic *STK11* deletions are a common cause of PJS and provide a strong rationale for conducting a primary screen for such mutations in patients.

Peutz-Jeghers syndrome (PJS; MIM 175200) is a rare, autosomal dominant cancer predisposition syndrome characterised by oro-facial pigmentation and hamartomatous polyposis of the gastrointestinal tract.¹ Depending on the patient population studied and analytical technique employed, a causative germline mutation in *STK11* can be identified in between 30% and 80% of PJS patients.²⁻⁴ Failure to identify mutations in all PJS patients coupled with the report of a possible second disease locus has fuelled considerable debate as to whether allelic heterogeneity or genetic heterogeneity is responsible for PJS in which no *STK11* mutation can be detected.⁵

Current screening methodologies for identifying *STK11* mutations in PJS are typically PCR based, using heteroduplex methods, denaturing high performance liquid chromatography, and/or direct sequencing of the nine coding exons of the gene, together with whole fluorescent in situ hybridisation with a single *STK11* probe or long range PCR. While these techniques can detect whole gene deletions and small scale intra-exonic deletions/insertions and point mutations, they are rarely capable of identifying deletions or duplications that encompass one or more exons. Such deletions are increasingly being recognised as being the mechanism of gene mutation in a number of cancer predisposition syndromes, such as hereditary breast-ovarian cancer syndrome, hereditary non-polyposis colorectal cancer, and Fanconi anaemia group A.⁶⁻⁸ Hence, the prevalence of *STK11* mutations in PJS may have been underestimated in previously reported studies.

Several methods have been used to identify exonic deletions and duplication, including Southern blotting, long range PCR, quantitative fluorescent PCR, real time PCR, multiplex amplification and probe hybridisation, and multiplex ligation dependent probe amplification (MLPA). Of these, MLPA has been shown to be a highly sensitive method for detecting copy number changes in genomic DNA sequences and to be readily adaptable for high throughput screening.⁹ The technique relies on the ligation and subsequent PCR amplification of two adjacently hybridising probes using fluorescently labelled universal oligonucleotides complementary to synthetic sequence tags present on every probe. Each probe is designed to ensure a spectrum of uniquely sized PCR products is generated that can be individually quantified by electrophoretic analysis.

Here we report on the spectrum and prevalence of the different types of *STK11* mutations in a series of 38 probands with PJS, specifically focusing on the possible contribution of exonic deletions to disease susceptibility. Analyses were restricted to British residents and clinical phenotype was not a selection criterion. In all cases the diagnosis of PJS was based on established clinical and pathological criteria.¹ To screen for exonic deletions and duplications we made use of the *STK11* MLPA assay kit, which has only recently become available (P101, MRC-Holland, Amsterdam, The Netherlands; www.mrc-holland.com). DNA was extracted from EDTA-venous blood samples using a standard salting-out procedure. Written consent was obtained from all participants and the study was conducted with local ethical approval in accordance with the tenets of the Helsinki declaration.

The 38 probands consisted of 15 males and 23 females (table 1). A family history of PJS had been documented in 21 (55%) of the probands. Using a combination of conformation sensitive gel electrophoresis, denaturing high performance liquid chromatography, and direct sequencing we identified germline *STK11* mutations in 19 of the 38 (50%) probands. Details of these analyses and PCR primers have been previously reported.⁴ Nucleotide changes identified were coded according to the published sequence of *STK11* (GenBank accession numbers: exon 1, AF032984; exons 2-8, AF032985; exon 9, AF032986) and mutations according to the Human Genome Variation Society (<http://www.hgvs.org/mutnomen/examplesAA.html>). The mutations detected in this phase of the analysis consisted of four nonsense mutations, six deletions, and two insertions predicted to lead to truncation of the expressed protein, four missense mutations, and three splice site mutations.

A search for exonic rearrangements was conducted by MLPA in the 19 PJS probands in whom no germline *STK11* mutation could be identified. This analysis was performed in

Abbreviations: MLPA, multiplex ligation dependent probe amplification; PJS, Peutz-Jeghers syndrome

Table 1 Clinical details and *STK11* mutation status of the 38 PJS probands studied

Patient identifier	Sex	Family history of PJS	Age at diagnosis (years)	Personal history of cancer	Family history of cancer	Mutation	Effect of mutation
Mutation positive							
PJS 048	M	+	2			c.180C>A	Y60X
PJS 038	M		7			c.153delG	M51fs
PJS 077	M	+	13		Cervix, CRC	c.208G>T	E70X
PJS 068	M		23			c.241A>T	K81X
PJS 036	F		7			c.336delG	Q112fs
PJS 060	F		16	Breast		c.368delA	Q123fs
PJS 052	F	+	18			c.454C>T	Q152X
PJS 056	F	+	8		Stomach	c.426delC	S142fs
PJS 024	F		20			c.717_718insA	W239fs
PJS 047	F	+	25			c.814_816insA	Y272X
PJS 042	F	+	10		Breast	c.843delG	P281fs
PJS 051	M	+	4			c.843delG	P281fs
PJS 059	F	+	4			c.470T>C	F157S
PJS 020	F	+	15			c.580G>A	D194N
PJS 045	F	+	10		Pancreas	c.725G>A	G242E
PJS 035	F	+	16	Breast	Breast	c.910C>T	R304W
PJS 069	F		21			c.733+1G>A	Splice site error
PJS 061	M	+	19			c.921-2A>G	Splice site error
PJS 033	M	+	31			c.921-2A>G	Splice site error
PJS 066	F		5			c.1-?_76+?del	Kinase domain deletion
PJS 115	F	+	34			c.1-?_76+?del	Kinase domain deletion
PJS 062	F	+	13			c.1-?_76+?del	Kinase domain deletion
PJS 055	M		15			c.333-?_424+?del	Kinase domain deletion
PJS 049	F	+	22			c333-?_1302+?del	Kinase domain deletion
PJS 039	M		11			c.1082-?_1183+?del	Regulatory domain deletion
Mutation negative							
PJS 001	F		5				
PJS 011	F		12	Astrocytoma			
PJS 025	M		20				
PJS 037	F	+	38				
PJS 040	M		26				
PJS 064	M		5				
PJS 067	M	+	2		Stomach		
PJS 070	F	+	3				
PJS 071	M	+	34				
PJS 099	F		<1				
PJS 102	M		6	Sertoli			
PJS 110	F		<1				
PJS 113	F	+	34		Prostate		

CRC, colorectal cancer.

accordance with the manufacturer's protocol (MRC-Holland). The *STK11* P101 assay is based on 28 probe sets: 13 that hybridise to the 10 exons and the 5' untranslated region of *STK11*, and three that map 0.6 mb telomeric, 0.9 mb telomeric, and 10 mb centromeric to the gene; 12 probes serve as controls that hybridise to distal regions of the genome. PCR products were detected and data were analysed using an ABI 3100 semi-automated genetic analyser in conjunction with Genotyper software (version 3.7; Applied Biosystems, Foster City, CA, USA). For each sample analysed ratios of test peak area and control peak area to the mean control peak area were computed. Ratios were compared to mean ratios obtained following analysis of 19 control DNA samples from healthy unrelated individuals in order to normalise data between samples and probes to generate dosage quotients. Results were deemed usable if dosage quotients for each control peak per sample were between 0.8 and 1.2. Deletions and duplications were defined as two or more contiguous probes with dosage quotients of ≤ 0.7 and ≥ 1.3 , respectively, in accordance with published recommendations.¹⁰ Figure 1 shows representative chromatograms obtained by MLPA analysis of the *STK11* gene.

MLPA analysis showed that six of the 19 PJS probands were carriers of exonic deletions (table 1): two unrelated cases with deletion of exon 1 and the 5' furthest upstream probe (c.1-?_76+?del), one with deletion of the 5' upstream sequence and exon 1 (c.1-?_76+?del), one with deletion of exons 2 and 3 (c.333-?_424+?del), one with deletion of

exons 2–10 (c.333-?_1302+?del), and one with deletion of exons 8 and 9 (c.1082-?_1183+?del). Figure 2 shows a representative ideogram of the mutations identified. For two of these cases (PJS 049: exons 2–10 deletion and PJS 062: exon 1 and 5' upstream deletion) DNA from an additional family member was available, and in both cases an identical peak profile was observed in affected relatives. It has been suggested that single exon deletions should be confirmed by other methods to exclude false positive results from MLPA analysis,⁸ as reduced dosage quotients could be a consequence of point mutations in the probe hybridisation sequence thereby reducing the probe's binding efficiency. It is, however, highly unlikely, that the deletions of multiple contiguous exons identified in this study represent false positives.⁸ All deletions identified in this report consist of multiple probe deletions and are, therefore, unlikely to represent false positive observations. Furthermore, two deletions were confirmed in affected family members and no reductions in test probe dosage quotients were observed in any of the 19 control samples tested. Neither of the two relatives evaluated had a personal history of malignancy.

All mutations causing PJS reported to date, including those reported in this manuscript, result in either loss of *STK11* kinase activity or disruption of *STK11* regulatory regions.¹¹ While large scale deletions of *STK11* have previously been reported in PJS including deletion of approximately 250 kb encompassing the entire *STK11* gene,¹² these appear to be rare. To date most screens for large deletions in *STK11* have




Figure 1 Representative chromatograms from MLPA analysis of *STK11*. (A) Control individual with peaks corresponding to exonic and 5' UTR probes; probes hybridising to flanking regions of *STK11* are indicated. All other peaks correspond to control probe signals. (B) Chromatogram from PJS patient PJS 049 showing the relative reduction in peak area of probes hybridising to exons 2–10 of *STK11*. (C) Chromatogram from PJS patient PJS 055 showing the relative reduction in peak area of probes hybridising to exons 2 and 3 of *STK11*.

been conducted using long range PCR. This has generally been based on amplification of exons 3–8, as an amplicon in excess of 20 kb is required to encompass the entire gene. It is apparent from this study that such analyses are inadequate as none of the exonic deletions reported in this study can be detected by long range PCR.

The findings of this study show that germline exonic deletions of *STK11* are not a rare cause of PJS: 16% (6/39) of the entire cohort of PJS patients (95% confidence limits: 6% to 31%), and 32% of patients in whom mutations had not been previously identified (95% confidence limits: 13% to 57%), are readily detectable by MLPA analysis. These findings provide a strong rationale for screening for exonic deletions in *STK11* in all PJS patients prior to conducting a

conventional screen for point mutations and small deletions/insertions.

Given that various relationships between genotype and phenotype have been reported in PJS,^{13 14} it is probable that patients harbouring exonic deletions may have different manifestations to carriers of missense mutations. The number of patients analysed in our study is, however, too small for such relationships to be realistically examined.

The notion of genetic heterogeneity in PJS is founded on the observation that mutations in *STK11* cannot always be identified in PJS patients, and evidence of genetic linkage of a PJS phenotype to 19q14 in a single family.⁵ Data from other mutational analyses of germline susceptibility suggest that the sensitivity of PCR based mutation detection methods is




Figure 2 Ideogram of *STK11* deletions detected in PJS patients. Thick bars indicate extent of deleted sequence; thin bars indicate largest possible extent of deletion.

~70%. Hence, if the number of patients having PCR detectable mutations is adjusted accordingly, then in our study point mutations and small scale deletions/insertions may account for up to 86% of PJS (upper 95% confidence limit). Coupled with the relatively high prevalence of exonic *STK11* deletions as a mechanism of disease susceptibility and the existence of cryptic splice sites as a cause of PJS¹⁵ means that almost all cases of the syndrome can be accounted for by *STK11* mutations, thereby bringing into question the existence of locus heterogeneity.

ACKNOWLEDGEMENTS

We are grateful to the patients who participated in this study.

ELECTRONIC-DATABASE INFORMATION



The website of MRC-Holland, Amsterdam, The Netherlands can be found at www.mrc-holland.com, and that of the Human Genome Variation Society can be found at <http://www.hgvs.org/mutnomen/examplesAA.html>

Authors' affiliations

N C M Hearle, M F Rudd, W Lim, R S Houlston, Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK

V Munday, Department of Medical Genetics, Yorkhill Hospital, Glasgow, UK

A G Lim, Department of Gastroenterology, Epsom General Hospital, Epsom, Surrey, UK

R K Phillips, Polyposis Registry, St Mark's Hospital, Harrow, Middlesex, UK

P W Lee, Department of Surgery, Hull Royal Infirmary, Hull, East Yorkshire, UK

J O'Donohue, Department of Gastroenterology, University Hospital Lewisham, London, UK

P J Morrison, Department of Medical Genetics, Belfast City Hospital, Belfast, UK

A Norman, Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK

S V Hodgson, Department of Clinical Genetics, St. Georges Hospital, London, UK

A Lucassen, Wessex Clinical Genetics Service, The Princess Anne Hospital, Southampton, UK

This work was supported by grants from Cancer Research UK

Conflict of interest: none declared

Correspondence to: Richard S Houlston, Section of Cancer Genetics, Brookes Lawley Building, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK; Richard.Houlston@icr.ac.uk

Revised version received 4 August 2005

Accepted for publication 8 August 2005

REFERENCES

- 1 **Tomlinson IP**, Houlston RS. Peutz-Jeghers syndrome. *J Med Genet* 1997;**34**:1007–11.
- 2 **Hemminki A**, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature* 1998;**391**:184–7.
- 3 **Jenne DE**, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W, Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. *Nat Genet* 1998;**18**:38–43.
- 4 **Lim W**, Hearle N, Shah B, Munday V, Hodgson SV, Lucassen A, Eccles D, Talbot I, Neale K, Lim AG, O'Donohue J, Donaldson A, Macdonald RC, Young ID, Robinson MH, Lee PW, Stoodley BJ, Tomlinson I, Alderson D, Holbrook AG, Vyas S, Swarbrick ET, Lewis AA, Phillips RK, Houlston RS. Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. *Br J Cancer* 2003;**89**:308–13.
- 5 **Mehenni H**, Blouin JL, Radhakrishna U, Bhardwaj SS, Bhardwaj K, Dixit VB, Richards KF, Bermejo-Fenoll A, Leal AS, Raval RC, Antonarakis SE. Peutz-Jeghers syndrome: confirmation of linkage to chromosome 19p13.3 and identification of a potential second locus, on 19q13.4. *Am J Hum Genet* 1997;**61**:327–34.
- 6 **Hogervorst FB**, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonck R, Menko FH, Kluijff I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. *Cancer Res* 2003;**63**:1449–53.
- 7 **Morgan NV**, Tipping AJ, Joenje H, Mathew CG. High frequency of large intragenic deletions in the Fanconi anemia group A gene. *Am J Hum Genet* 1999;**65**:1330–41.
- 8 **Taylor CF**, Charlton RS, Burn J, Sheridan E, Taylor GR. Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA. *Hum Mutat* 2003;**22**:428–33.
- 9 **Schouten JP**, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. *Nucleic Acids Res* 2002;**30**:e57.
- 10 **Bunyan DJ**, Eccles DM, Sillibourne J, Wilkins E, Thomas NS, Shea-Simonds J, Duncan PJ, Curtis CE, Robinson DO, Harvey JF, Cross NC. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. *Br J Cancer* 2004;**91**:1155–9.
- 11 **Boudeau J**, Sapkota G, Alessi DR. LKB1, a protein kinase regulating cell proliferation and polarity. *FEBS Lett* 2003;**546**:159–65.
- 12 **Le Meur N**, Martin C, Saugier-Verber P, Joly G, Lemoine F, Moirrot H, Rossi A, Bachy B, Cabot A, Joly P, Frebourg T. Complete germline deletion of the STK11 gene in a family with Peutz-Jeghers syndrome. *Eur J Hum Genet* 2004;**12**:415–18.
- 13 **Amos CI**, Keitheri-Cheteri MB, Sabripour M, Wei C, McGarrity TJ, Seldin MF, Nations L, Lynch PM, Fidler HH, Friedman E, Frazier ML. Genotype-phenotype correlations in Peutz-Jeghers syndrome. *J Med Genet* 2004;**41**:327–33.
- 14 **Schumacher V**, Vogel T, Leube B, Driemel C, Goecke T, Moslein G, Royer-Pokora B. STK11 genotyping and cancer risk in Peutz-Jeghers syndrome. *J Med Genet* 2005;**42**:428–35.
- 15 **Abed AA**, Gunther K, Kraus C, Hohenberger W, Ballhausen WG. Mutation screening at the RNA level of the STK11/LKB1 gene in Peutz-Jeghers syndrome reveals complex splicing abnormalities and a novel mRNA isoform (STK11 c.597(insertion mark)598insIVS4). *Hum Mutat* 2001;**18**:397–410.